The nation of Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years over the United States' demand for confidential information.
This move was revealed after a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesman later stated that the US was seeking health data for research and commercial gain while was not willing to share the resulting advantages from any future vaccines.
"We are forced to start the difficult and regrettable task of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged more negotiations to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Implications
Zimbabwe's decision follows a comparable case in Kenya, where a high court suspended a related deal with the US after legal challenges were raised about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government deals to enhance transparency and responsibility.
According to reports, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million presently on antiretroviral therapy via American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data for a long time, without any equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," he stated.
"Effectively, our nation would supply the basic resources for scientific discovery with no assurance that the final treatments would be accessible to our citizens should a new disease outbreak arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending systems previously established via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This system is intended to guarantee that when a nation provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our US partners on how subsequent collaboration might be designed in a manner that respects the independence and interests of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that talks should continue since much of the country's Aids initiatives were funded by foreign aid.
"Where technical issues exist, including those relating to data governance or agreement terms, these can often be addressed via detailed discussion and mutually agreed protections," the group said.
The situation underscores the complex challenges between accepting much-needed foreign assistance and protecting a country's data in an ever more interconnected world.